

Resistant Starch as a complementary treatment for type 2 diabetes

Submission date
18/11/2011

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
18/11/2011

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
21/04/2015

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Denise Robertson

Contact details
University of Surrey
Diabetes and Endocrinology
Postgraduate Medical School
London
United Kingdom
GU2 7WG
+44 (0)148 3 68 6407
m.robertson@surrey.ac.uk

Additional identifiers

Protocol serial number
8870

Study information

Scientific Title
Resistant Starch as a complementary treatment for type 2 diabetes

Acronym

DRN 505 (Resistant Starch treatment for T2DM)

Study objectives

Dietary fibres in the diet, such as resistant starch, are known to have many health benefits especially regarding large-bowel health. Resistant starch is of particular interest as it can be easily incorporated into everyday foods without affecting the appearance, taste or texture of that food. Fibres are fermented in the large-bowel by the resident bacteria releasing metabolites known as short-chain fatty acids. These short-chain fatty acids are absorbed into the general circulation and are believed to underlie the other health benefits of dietary fibre, namely increasing the bodies' responsiveness to the hormone insulin and so reducing the risk of developing conditions such as high blood-pressure, type 2 diabetes and heart disease.

Initial studies in our group have shown that resistant starch has beneficial effects on the insulin response in healthy subjects and those at risk of developing diabetes. Due to these findings the current study has been designed to look at the effects of resistant starch in subjects who have well controlled type 2 diabetes and investigate whether there is an improvement in glycaemic control when resistant starch is consumed in addition to an individual's normal diet and treatment.

Participants will be asked to consume the resistant starch or an energy and carbohydrate matched placebo everyday for 12 weeks. At the end of each 12 week period the participants will be asked to attend for 3 study visits where the effects on glycaemic control, insulin sensitivity and body fat storage (by MRI scanning) will be assessed.

The overall aim of the study is to conduct a placebo-controlled crossover dietary intervention study using 40 g/day RS for 12 weeks in patients diagnosed with type 2 diabetes mellitus (T2DM). The following measurements will be taken and compared between the interventions:

1. Insulin sensitivity
2. Changes to glycaemic control
3. HbA1c, fasting insulin sensitivity by homeostatic model assessment (HOMA), plasma lipids

More details can be found here: <http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=8870>

Ethics approval required

Old ethics approval format

Ethics approval(s)

10/H1101/29

Primary study design

Interventional

Study design

Randomised; Interventional; Design type: Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Diabetes Research Network, Primary Care Research Network for England; Subtopic: Type 2, Not Assigned; Disease: Diabetic Control, Metabolic, Nutrition

Interventions

Dietary Intervention, 40g/day resistant starch for weeks compared to matched placebo; Study Entry : Single Randomisation only

Intervention Type

Supplement

Primary outcome(s)

- 11. Glycaemic control
 - 1.1. Hyperinsulinaemic clamp with stable isotopes
 - 2. HbAc
 - 3. Fasting glucose and insulin
- Measured at end of intervention

Key secondary outcome(s)

- 1. Ectopic fat distribution
 - 1.1. Whole body magnetic resonance imaging (MRI)
 - 2. Vascular function
 - 2.1. Blood pressure and pulse wave analysis
- Measured at end of intervention

Completion date

29/02/2012

Eligibility

Key inclusion criteria

- 1. Males and Females, aged 20 - 65 years
- 2. Those with T2DM, that has been diagnosed for > 2 years, and
- 3. Are either diet / exercise controlled or on metformin treatment (or both), which has not been modified in 6 months.

Target Gender: Male & Female; Upper Age Limit 65 years ; Lower Age Limit 20 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Those who control their diabetes by insulin or sulphonylureas
2. Those with an HbA1c ≥ 8.5 indicative of poor control
3. Those with certain medical conditions (for example heart disease, gastrointestinal disease, liver disease, type 1 diabetes or endocrine diseases)
4. Those known to suffer from claustrophobia or have metal implants as this would prevent Magnetic resonance spectroscopy (MRS) scanning

Date of first enrolment

01/06/2010

Date of final enrolment

29/02/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University of Surrey

London

United Kingdom

GU2 7WG

Sponsor information

Organisation

University of Surrey (UK)

ROR

<https://ror.org/00ks66431>

Funder(s)

Funder type

Charity

Funder Name

Diabetes UK (UK)

Alternative Name(s)

The British Diabetic Association, DIABETES UK LIMITED, British Diabetic Association

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/04/2014		Yes	No